Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oral PTL101 (cannabidiol) as an adjunctive treatment for pediatric intractable epilepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy Intractable

Drugs mentioned

• PTL101 (cannabidiol)

Snippet

Sponsor: PhytoTech Therapeutics, Ltd. | Conditions: Epilepsy Intractable | Phase 2 | Status: COMPLETED